Novo Nordisk NVO new weightloss PILL success
Posted: Jan 24, 2025
- Novo Nordisk successfully completed a phase 1B/2A trial with subcutaneous amycretin in people with overweight or obesity
- Trial investigated safety, tolerability, pharmacokinetics, and proof-of-concept in 125 individuals
- Results showed weight loss potential with amycretin, with participants achieving significant weight loss compared to a placebo group
- Novo Nordisk is planning further clinical development of amycretin in adults with overweight or obesity
- Novo Nordisk is a leading global healthcare company founded in Denmark, focused on defeating chronic diseases, particularly diabetes
- Stock tickers: $NVO (Novo Nordisk A/S)
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!